Mettler-Toledo International (MTD)
NYSE:MTD
Top Page
Mettler-Toledo
(NYSE:MTD)
Select Model
Select Model
Rating:66Neutral
Price Target:
$1,331.00
▲(4.80% Upside)
Action:ReiteratedDate:02/07/26
The score is primarily supported by strong profitability and free-cash-flow generation plus constructive FY2026 guidance and buybacks. Offsetting this are meaningful balance-sheet risk from high leverage/negative equity, weak current technical momentum, and a premium valuation (P/E ~32.6) that raises execution expectations.
Positive Factors
High profitability and margins
Sustained high gross and operating margins reflect durable pricing power, product differentiation and cost structure advantages in precision instruments. Strong margins support reinvestment in new products, cover cyclical downturns, and underpin long-term earnings resilience even if top-line growth moderates.
Negative Factors
High leverage and negative shareholders' equity
Material leverage and negative equity raise structural financial risk: higher interest and covenant sensitivity can limit capital allocation flexibility, constrain opportunistic investments or M&A, and make the company more vulnerable to demand shocks despite strong cash flow generation.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability and margins
Sustained high gross and operating margins reflect durable pricing power, product differentiation and cost structure advantages in precision instruments. Strong margins support reinvestment in new products, cover cyclical downturns, and underpin long-term earnings resilience even if top-line growth moderates.
Read all positive factors
Mettler-Toledo (MTD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.81B
Dividend YieldN/A
Average Volume (3M)173.29K
Price to Earnings (P/E)33.1
Beta (1Y)1.08
Revenue Growth4.77%
EPS Growth7.93%
CountryUS
Employees16,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)13.36
Shares Outstanding20,325,250
10 Day Avg. Volume157,867
30 Day Avg. Volume173,294
Financial Highlights & Ratios
PEG Ratio8.96
Price to Book (P/B)-1.22K
Price to Sales (P/S)7.14
P/FCF Ratio33.86
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.98
Enterprise Value/Gross Profit12.13
Enterprise Value/Ebitda22.63
Forecast
1Y Price Target
$1,479.71Price Target Upside16.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)46.5
Revenue Forecast (FY)$4.23B
Mettler-Toledo Business Overview & Revenue Model
Company Description
Mettler-Toledo International Inc. engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. T...
How the Company Makes Money
Mettler-Toledo makes money primarily by selling precision instruments and related software into laboratory and industrial end markets, and by earning recurring revenue from services and consumables that support its installed base. Key revenue stre...
Mettler-Toledo Key Performance Indicators (KPIs)
Any
Revenue By Segment
Analyzes income from different business segments, highlighting which areas drive growth and profitability, and where the company might be vulnerable or have expansion opportunities.
Analyzes income from different business segments, highlighting which areas drive growth and profitability, and where the company might be vulnerable or have expansion opportunities.
Data provided by:
The Fly
The FlyMettler-Toledo Earnings Call Summary
Earnings Call Date:Feb 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call presented a generally positive operational and financial story: the company delivered broad-based sales growth, strong adjusted EPS performance, exceptional free cash flow conversion, clear product and service milestones, and constructive guidance for FY2026 (sales ≈4%, EPS growth 8–9%). Material headwinds remain from tariffs, unfavorable foreign exchange, and margin compression in the recent period, and management is conservatively guiding Q1 given market caution. On balance the positive execution, cash generation, product momentum and maintained/raised guidance outweigh the disclosed challenges.Positive Updates
Quarterly Sales Growth
Q4 sales of $1.1 billion; local-currency sales up 5% (4% excluding previously communicated acquisitions); reported U.S. dollar sales up 8%.
Negative Updates
Gross Margin and Tariff Headwinds
Q4 gross margin 59.8%, down 140 basis points vs. prior year; incremental gross tariff costs were a ~190 basis-point headwind in the quarter and management estimated tariffs reduced operating profit by ~7% in Q4; FY2025 tariffs were a ~$50 million headwind (≈130 bps to operating margin) and reduced EPS growth by ~5%.
Read all updates
Q4-2025 Updates
Positive
Negative
Quarterly Sales Growth
Q4 sales of $1.1 billion; local-currency sales up 5% (4% excluding previously communicated acquisitions); reported U.S. dollar sales up 8%.
Read all positive updates
Company Guidance
The company guided 2026 local-currency sales growth of approximately 4% (about 3.5% excl. previously announced acquisitions) with Q1 local-currency sales of ~3%; adjusted EPS for the full year of $46.05–$46.70 (up 8–9%) and Q1 EPS of $8.60–$8.75 (up 5–7%); operating margin expected to be up 60–70 basis points excluding currency (reported margin flat to slightly up), while Q1 margin is expected to be down ~100 bps at the midpoint (flat excl. unfavorable currency); guidance assumes current U.S. import and retaliatory tariffs remain in effect and does not assume a material market improvement versus 2025; FX at recent spot rates is estimated to be about a 1% benefit to full‑year sales (slight EPS headwind) and roughly a 4% benefit to Q1 sales (neutral to EPS); additional financial assumptions include total amortization ≈$78M (purchased intangible amortization ≈$27M pretax, ≈$1.04 excluded from adjusted EPS), interest expense ≈$70M, other income ≈$19M, a pre‑discrete tax rate of ~19%, free cash flow of ≈$900M (≈+5% per share) with Q1 FCF ≈$100M, and share repurchases of $825M–$875M.Mettler-Toledo Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
38
Negative
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.03B | 3.87B | 3.79B | 3.92B | 3.72B |
| Gross Profit | 2.32B | 2.25B | 2.17B | 2.24B | 2.11B |
| EBITDA | 1.23B | 1.22B | 1.18B | 1.24B | 1.10B |
| Net Income | 869.19M | 863.14M | 788.78M | 872.50M | 768.99M |
Balance Sheet | |||||
| Total Assets | 3.71B | 3.24B | 3.36B | 3.49B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 66.89M | 59.36M | 69.81M | 95.97M | 98.56M |
| Total Debt | 2.34B | 2.13B | 2.20B | 2.13B | 1.80B |
| Total Liabilities | 3.74B | 3.37B | 3.51B | 3.47B | 3.16B |
| Stockholders Equity | -23.64M | -126.89M | -149.94M | 24.79M | 171.42M |
Cash Flow | |||||
| Free Cash Flow | 848.65M | 864.45M | 860.55M | 737.83M | 801.25M |
| Operating Cash Flow | 955.77M | 968.35M | 965.87M | 859.07M | 908.83M |
| Investing Cash Flow | -193.87M | -119.46M | -131.69M | -139.40M | -314.11M |
| Financing Cash Flow | -755.17M | -855.98M | -859.59M | -716.04M | -590.55M |
Mettler-Toledo Technical Analysis
Neutral
1270.00
Price Trends
1312.44
Negative
1372.42
Negative
1325.31
Negative
Market Momentum
-11.91
Negative
50.06
Neutral
62.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTD, the sentiment is Neutral. The current price of 1270 is above the 20-day moving average (MA) of 1231.20, below the 50-day MA of 1312.44, and below the 200-day MA of 1325.31, indicating a neutral trend. The MACD of -11.91 indicates Negative momentum. The RSI at 50.06 is Neutral, neither overbought nor oversold. The STOCH value of 62.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MTD.
Mettler-Toledo Risk Analysis
Mettler-Toledo disclosed 29 risk factors in its most recent earnings report. Mettler-Toledo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mettler-Toledo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | $21.62B | 19.42 | 13.88% | 1.80% | 13.74% | 14.87% | |
67 Neutral | $135.07B | 44.80 | 6.99% | 0.53% | 2.90% | -4.81% | |
66 Neutral | $25.81B | 33.06 | -487.21% | ― | 4.77% | 7.93% | |
66 Neutral | $32.45B | 31.05 | 19.73% | 0.72% | 6.73% | 3.34% | |
66 Neutral | $30.15B | 35.17 | 28.52% | ― | 6.90% | 3.86% | |
63 Neutral | $181.84B | 32.34 | 13.15% | 0.30% | 3.91% | 7.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MTD
Mettler-Toledo
1,270.00
208.34
19.62%
A
Agilent
113.88
7.70
7.25%
DHR
Danaher
191.01
0.43
0.23%
DGX
Quest Diagnostics
196.81
35.66
22.13%
TMO
Thermo Fisher
489.50
37.61
8.32%
WAT
Waters
307.38
-29.14
-8.66%
Mettler-Toledo Corporate Events
Executive/Board Changes
Mettler-Toledo Adds Experienced Independent Director to Board
Positive
Jan 20, 2026
On January 16, 2026, Mettler-Toledo’s board appointed Michael J. Tokich as an independent director, effective February 5, 2026, expanding the board from nine to ten members with compensation aligned to the company’s other independent d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.